GlassScriptPhysician profile
Chad A Winters
NPI 1710942891
$10,066.26
in general payments reported to CMS, 2019-2025
72 companies · $976 in 2025
The $976 reported for 2025 was more than what 85% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,581 · 2020: $1,638 · 2021: $1,906 · 2022: $1,275 · 2023: $1,552 · 2024: $1,138 · 2025: $976.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,665.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,665.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,184.98 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $1,165.24 | 2019-2025 | Vraylar, Ubrelvy, Qulipta |
| Pfizer INC. | $1,006.67 | 2019-2025 | |
| Lilly USA, LLC | $728.47 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $565.21 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $524.78 | 2019-2024 | Jardiance, Tradjenta, Synjardy |
| Amgen INC. | $501.94 | 2019-2025 | Evenity, Prolia, Otezla |
| Glaxosmithkline, LLC. | $317.32 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amarin Pharma, INC. | $309.75 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $229.93 | 2019-2023 | Belsomra, Steglatro |
| Teva Pharmaceuticals USA, INC. | $226.73 | 2020-2024 | Austedo Xr, Austedo |
| Janssen Pharmaceuticals, INC | $212.86 | 2019-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $202.20 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $172.00 | 2019-2023 | Trintellix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $170.67 | 2020-2024 | Xifaxan |
Show all 72 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chad Winters listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.